Scarica l'app Stockscreener
112.77
0.12%
0.13
Dopo l'orario di chiusura:
112.77
Precedente Chiudi:
$112.64
Aprire:
$109.79
Volume 24 ore:
591.43K
Relative Volume:
0.76
Capitalizzazione di mercato:
$6.55B
Reddito:
$507.44M
Utile/perdita netta:
$-187.69M
Rapporto P/E:
-34.48
EPS:
-3.271
Flusso di cassa netto:
$-39.06M
1 W Prestazione:
+4.66%
1M Prestazione:
-6.89%
6M Prestazione:
+33.47%
1 anno Prestazione:
+12.72%
Intervallo 1D:
$108.72
$113.89
Intervallo di 1 settimana:
$102.12
$113.89
Portata 52W:
$73.16
$130.23
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
112.77 | 6.55B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Q4 2024 Glaukos Corp Earnings Call Transcript - GuruFocus
Glaukos (NYSE: GKOS) CDO reports RSU tax withholding transactions - Stock Titan
Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations - Stock Titan
Glaukos (GKOS) president uses 3,169 shares to cover tax withholding - Stock Titan
Glaukos (GKOS) CEO gifts 180,308 shares to family trust - Stock Titan
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Cash per share of Glaukos Corp – DUS:6GJ - TradingView
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules - ChartMill
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
GLAUKOS (GKOS) CDO has 5,798 shares withheld to cover RSU tax - Stock Titan
GKOS PE Ratio & Valuation, Is GKOS Overvalued - intellectia.ai
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS - MarketBeat
Why Glaukos Stock Jumped Over 20% After-Hours Today - MSN
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
GKOS SEC FilingsGlaukos Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock - MarketBeat
Glaukos SVP Thurman sells $267k in GKOS stock - Investing.com
Glaukos SVP Thurman sells $267k in GKOS stock By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) president reports new stock and option grants - Stock Titan
Glaukos (NYSE: GKOS) CFO gets new equity awards and sells shares - Stock Titan
Glaukos Corporation (NYSE:GKOS): Is Breakeven Near? - 富途牛牛
Glaukos launches Epioxa, boosts growth in corneal treatments - MSN
Riverbridge Partners LLC Sells 34,475 Shares of Glaukos Corporation $GKOS - MarketBeat
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For KeratoconusWhat's Changed - simplywall.st
Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS) - Stock Titan
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock - MarketBeat
Glaukos CFO Thurman sells $160k in shares By Investing.com - Investing.com South Africa
Glaukos CFO Thurman sells $160k in shares - Investing.com
Glaukos (GKOS) CEO uses 2,744 shares to cover equity tax withholding - Stock Titan
Glaukos (GKOS) president sees 15,118 shares withheld to cover tax obligations - Stock Titan
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares - Stock Titan
Glaukos (NYSE: GKOS) CFO sale and tax share withholdings detailed - Stock Titan
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting - Stock Titan
Glaukos Corp Stock Faces Monthly Pressure Amid Analyst Optimism and Glaucoma Innovation Push - AD HOC NEWS
Piper Sandler reiterates Glaukos stock rating on growth outlook - Investing.com UK
Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com - Investing.com Australia
Why is Glaukos (GKOS) down 14.7% since last earnings report? - MSN
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS - marketbeat.com
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy - Bitget
Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care - marketscreener.com
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments - Yahoo Finance Singapore
Glaukos (GKOS) Launches Epioxa HD for Keratoconus Treatment - GuruFocus
Glaukos Corporation (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care - visionmonday.com
Glaukos SVP Thurman sells $61,968 in GKOS stock By Investing.com - Investing.com India
Navratil, Glaukos corp officer, sells $101k in GKOS stock By Investing.com - Investing.com Australia
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):